Today: 27 April 2026
Texas Instruments (TXN) stock price jumps to a 52-week high — what traders watch next
3 February 2026
1 min read

Texas Instruments (TXN) stock price jumps to a 52-week high — what traders watch next

New York, Feb 2, 2026, 19:45 (EST) — Trading continued after the bell

  • Texas Instruments shares surged 4.4%, closing at $225.01 to hit a new 52-week high.
  • Volume topped typical ranges, as semiconductor buyers stayed firm through to the closing bell.
  • All eyes are on the company’s Feb. 24 capital management webcast as a busy week looms, loaded with key macro data and big tech happenings.

Texas Instruments Incorporated (TXN) shares surged 4.4%, closing Monday at $225.01 to mark a new 52-week high. Volume soared past 11.2 million shares, well above the 50-day average near 7.5 million. The stock’s jump outpaced Nvidia, which dipped about 2.9% in the same session.

Texas Instruments remains a bellwether for “analog” chip demand—those crucial components that manage power and convert real-world signals for computers across industries like manufacturing, automotive, and data centers. The company’s guidance for Q1 revenue lands between $4.32 billion and $4.68 billion, with EPS from $1.22 to $1.48, both ahead of consensus estimates from LSEG. CEO Haviv Ilan pointed to a 70% surge in data-center revenue during the December quarter. “With the inventory correction … essentially complete,” noted Stifel’s Tore Svanberg. Reuters

The broader market provided some lift. The S&P 500 rose 0.54% on Monday, narrowly missing a record close. Chipmakers were in demand—Advanced Micro Devices surged 4.0%, and Micron Technology gained 5.5%. Investors stayed tuned ahead of this week’s Federal Reserve meeting.

After the close, a filing showed board member Robert E. Sanchez received restricted stock units and stock options dated Jan. 29 as part of his director pay. He was awarded 525 shares and options for 1,860 shares, with an exercise price set at $218.97.

The stock’s jump to fresh highs has put the spotlight on Texas Instruments’ choice between pouring cash into capacity expansion and rewarding shareholders. This tug-of-war has stirred up debate. While some investors see the expansion as a strategic bet for the long haul, others want more proof it’ll translate into stronger cash flow.

Texas Instruments said its board greenlit a quarterly dividend of $1.42 per share. The payout is scheduled for Feb. 10 to shareholders on record as of Jan. 30.

But those same tailwinds could flip fast if demand drops off. A global memory-chip shortage has already weighed on smartphone and PC sales—both major markets for Texas Instruments. Morgan Stanley, however, sees a supply crunch for the chipmaker as unlikely given the low utilization rates in factories worldwide. The firm also pointed to ongoing geopolitical risks as a wildcard. “Conditions are improving,” said Louise Dudley, portfolio manager at Federated Hermes, speaking on the broader supply chain. Reuters

Regular trading ended, and after-hours action tapered off. The spotlight now shifts to Tuesday, when investors will assess whether the chip rally holds up amid a packed week of macroeconomic reports and tech earnings.

Texas Instruments will webcast a capital management review on Feb. 24 at 10 a.m. Central time. CEO Ilan and CFO Rafael Lizardi are slated to present.

Stock Market Today

  • Structure Therapeutics (GPCR) Valuation Falters Amid Share Price Decline
    April 26, 2026, 10:46 PM EDT. Structure Therapeutics (GPCR) shares dropped to $45.49, marking a 49.21% decline over 90 days despite a strong 91.62% one-year total return. The biotech's price-to-book (P/B) ratio of 2.1x appears undervalued versus peers' average of 31.2x and the US pharmaceuticals sector average of 2.6x, suggesting cautious investor sentiment. This ratio compares market value to book value, often used for early-stage or loss-making companies. GPCR faces risks from ongoing clinical trials for GSBR-1290 and significant net losses of $141.2 million. Analyst forecasts predict 56.5% annual revenue growth, but uncertainties linger. Investors should balance potential gains with risks, monitoring clinical outcomes and funding capabilities amid a volatile healthcare sector.

Latest article

Kratos Defense Stock Slides Again as Drone Maker’s $1 Billion Growth Bet Faces Test

Kratos Defense Stock Slides Again as Drone Maker’s $1 Billion Growth Bet Faces Test

26 April 2026
Kratos Defense shares dropped 6.5% to $61.26, cutting its market value to $10.6 billion as investors questioned the pace of profit from new contracts. The company recently completed the first flight of its Mk1 Firejet drone and won a Space Force contract worth up to $446.8 million. AeroVironment, L3Harris, and Northrop Grumman also declined. Kratos raised $1.17 billion in a February share offering.
Robinhood’s Earnings Week Now Has a Prediction-Market Problem

Robinhood’s Earnings Week Now Has a Prediction-Market Problem

26 April 2026
Wisconsin sued Robinhood and several rivals over sports event contracts, alleging illegal sports betting through prediction markets. The lawsuit comes days before Robinhood reports first-quarter earnings on Tuesday. Robinhood shares closed at $84.71 Friday, down from $91.28 on Monday. The company said its event contracts are federally regulated and it will defend itself.
SoFi Technologies Stock Faces a Big Q1 Earnings Test as Loan Growth Comes Into Focus

SoFi Technologies Stock Faces a Big Q1 Earnings Test as Loan Growth Comes Into Focus

26 April 2026
SoFi will report first-quarter results before markets open April 29, with management projecting about $1.04 billion in adjusted net revenue and adjusted EPS of 12 cents. Shares closed at $18.44 Friday, valuing the company at $23.8 billion. The company recently launched a digital HELOC and formed a Real Estate Advisory Council. Last quarter, loan originations rose 46% to $10.5 billion and fee-based revenue climbed 53%.
Visa stock price jumps nearly 4% as V rebounds; traders eye jobs-report delays next
Previous Story

Visa stock price jumps nearly 4% as V rebounds; traders eye jobs-report delays next

Lumentum stock price jumps 8% ahead of Feb. 3 earnings — what investors watch next
Next Story

Lumentum stock price jumps 8% ahead of Feb. 3 earnings — what investors watch next

Go toTop